⚠ Evidence warning: Clinical trials or other evidence do not support the claim that silymarin is a useful add-on for hepatitis B or C symptoms and long-term liver protection. This page keeps it as a report of what people, websites or other media say.
Milk Thistle as Hepatitis Adjunctive Therapy
The story of milk thistle in chronic viral hepatitis is the most instructive case study in herbal medicine of how the evidence-base evolves as trial quality improves. From the 1980s through the early 2000s, milk thistle was widely promoted (especially in the United States) as a "treatment" for chronic hepatitis C based on small open-label trials showing reduced serum aminotransferases. The 2012 SyNCH trial — a properly powered U.S. National Institutes of Health-sponsored randomized placebo-controlled study of high-dose silymarin in interferon-failed hepatitis C virus (HCV) patients — produced unambiguously negative results: no benefit on serum alanine aminotransferase (ALT), on HCV RNA or on quality of life; the trial did not measure liver histology. At roughly the same time, the arrival of direct-acting antivirals (sofosbuvir, ledipasvir, glecaprevir, and successors) made hepatitis C virus definitively curable in over 95% of treated patients within 8-12 weeks. Milk thistle's role in hepatitis C virus has therefore been definitively recast: not a treatment of the virus, but an add-on that practitioners and patients describe using for symptomatic relief, fatigue, quality of life, and ongoing hepatic-cell-membrane stabilization during and after antiviral therapy. The hepatitis B virus (HBV) evidence is similar but smaller. This page walks through the trial history, the 2012 SyNCH inflection point, the modern hepatitis B virus/hepatitis C virus adjunct framework, and the silybin-phosphatidylcholine complex (IdB 1016), a form made to be better absorbed.
Table of Contents
- The Hepatitis C Virus Adjunct Question
- Early Open-Label and Small Randomized Controlled Trial Era (1980s-2000s)
- The HALT-C Lead-In Analysis (2008)
- The SyNCH Trial (2012) — The Inflection Point
- The Direct-Acting Antiviral (DAA) Era and the Modern Reframing
- Intravenous Silibinin in Hepatitis C Virus Salvage Therapy
- Hepatitis B Evidence Base
- Silybin-Phosphatidylcholine Complex (IdB 1016) and Absorption
- Standardized Silymarin and Quality Differences
- Doses Used in Trials and Described by Practitioners
- Symptom and Quality-of-Life Effects
- Cautions and Antiviral Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
The Hepatitis C Virus Adjunct Question
Hepatitis C virus (HCV) infection chronically affects an estimated 50-70 million people worldwide, including about 2.2 million United States adults during January 2017 to March 2020 in a U.S. Centers for Disease Control and Prevention (CDC) analysis, one third of them unaware of it, with substantially higher rates among people who are uninsured or poor (an earlier estimate was approximately 2.4 million). Untreated chronic hepatitis C virus leads to cirrhosis in 15-30% of patients over 20-30 years, with subsequent risk of hepatocellular carcinoma. The disease was, for decades, the principal indication for liver transplantation in developed countries.
The therapeutic landscape transformed completely between 2013 and 2018 with the introduction of direct-acting antivirals (DAAs) — combination regimens of sofosbuvir, ledipasvir, velpatasvir, glecaprevir, pibrentasvir, and others — that achieve sustained virologic response (cure) in over 95% of treated patients with 8-12 week oral courses. Hepatitis C virus is now considered curable for essentially anyone with access to treatment.
The question this page addresses is therefore not "does milk thistle treat hepatitis C virus" — we know the answer is no — but the more nuanced question: "what role, if any, does milk thistle play as an adjunct in hepatitis C virus patients?" The patient populations of interest are: (1) hepatitis C virus patients before they start DAA therapy (often a wait of weeks to months for prior-authorization or insurance approval), (2) hepatitis C virus patients during DAA therapy (potential symptomatic and hepatocellular support), (3) hepatitis C virus patients after DAA cure who have residual hepatic damage (cirrhosis, fibrosis, persistent alanine aminotransferase elevation), and (4) hepatitis C virus patients who cannot access or cannot tolerate DAAs.
Practitioners describe silymarin as an add-on for all four populations, based on its general hepatoprotective profile, but it does not affect the virus or change the trajectory of viral disease. The relevant outcomes are symptomatic and biochemical (alanine aminotransferase/aspartate aminotransferase (AST) reduction, fatigue, quality of life), not virologic.
Early Open-Label and Small Randomized Controlled Trial Era (1980s-2000s)
The early enthusiasm for milk thistle in chronic hepatitis came from a series of small, mostly open-label, mostly European studies in the 1980s and 1990s. Representative results:
- Buzzelli et al. (1993) — 20 patients with chronic active hepatitis were randomly assigned to a silybin-phosphatidylcholine complex (IdB 1016), 240 mg of silybin twice daily (10 patients), or placebo (10 patients) for 7 days. In the treated group, serum aspartate aminotransferase fell from 88.0 to 65.9 U/L and alanine aminotransferase from 115.9 to 82.5 U/L. A small pilot study with a placebo group.
- A reported 1992 trial — described in older accounts as 60 patients with chronic active hepatitis (mixed alcoholic and viral) randomized to a silybin-phosphatidylcholine complex 120 mg three times daily versus placebo for 60 days, with significant reductions in serum aminotransferases in the silymarin arm. No record of it could be found in PubMed, Europe PMC or Crossref.
- Mayer KE et al. (2005) — systematic review of chronic viral hepatitis: of 148 papers on silymarin in liver disease, four trials included patients with hepatitis C, one included hepatitis B patients and two included unspecified chronic viral hepatitis. Serum transaminases fell compared with baseline in four studies and compared with placebo in only one. The authors found no evidence that silymarin affects viral load or improves liver histology.
These early results drove widespread off-label use of milk thistle for chronic hepatitis throughout the 1990s and 2000s, particularly in the United States where conventional hepatitis C virus therapy (interferon alpha plus ribavirin) had cure rates of only 30-50% with significant toxicity. Many hepatitis C virus patients turned to integrative medicine, and milk thistle was the most-recommended herbal supplement in that setting.
The pattern of evidence — small trials, soft endpoints (transaminases rather than viral load or fibrosis), open-label or inadequate blinding — was a classic setup for the larger, more rigorous trials of the late 2000s to deliver disappointing results.
The HALT-C Lead-In Analysis (2008)
The HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) trial was a large U.S. National Institutes of Health-sponsored multicenter trial of long-term low-dose interferon for prevention of cirrhosis progression in hepatitis C virus. As a substudy, the investigators (Seeff et al., Hepatology 2008) analyzed milk thistle use among the 1,145 enrolled hepatitis C virus patients.
Findings:
- 17% of hepatitis C virus patients reported milk thistle use at baseline (consistent with widespread off-label use in this population)
- Milk thistle users had similar serum alanine aminotransferase to non-users, against the prediction from the open-label literature: "No beneficial effect of silymarin was found on serum alanine aminotransferase or hepatitis C virus (HCV) RNA levels"
- Milk thistle users did not have lower hepatitis C virus viral load
- Users reported fewer symptoms and somewhat better quality-of-life scores. The investigators concluded that, because use was self-motivated and uncontrolled, only a well-designed prospective study could determine whether silymarin benefits people with chronic hepatitis C
This was an early sign, on a large dataset, that the transaminase reduction seen in earlier small trials might not hold up. The HALT-C analysis was observational rather than randomized, but the size and quality of the dataset (1,145 patients with detailed clinical follow-up) made it influential. The investigators called for a well-designed prospective study, and SyNCH was the randomized trial that followed.
The SyNCH Trial (2012) — The Inflection Point
The SyNCH trial (Silymarin in non-alcoholic steatohepatitis (NASH) and C Hepatitis) was the long-awaited U.S. National Institutes of Health-funded (National Center for Complementary and Alternative Medicine), definitive randomized placebo-controlled trial of silymarin in chronic hepatitis C virus. Design: 154 patients with chronic hepatitis C virus and serum alanine aminotransferase of 65 U/L or greater who had failed prior interferon-based therapy, randomized to one of three arms for 24 weeks:
- Placebo (52 patients)
- Silymarin 420 mg three times daily (50 patients)
- Silymarin 700 mg three times daily (52 patients) — high-dose arm
The silymarin preparation was a standardized dry extract of milk thistle fruits, approved as a prescription drug in several countries of Europe and Asia and the same kind of extract used in the European cirrhosis trials (a silymarin content of 89.4% has been quoted for it; the trial's main text does not state that figure). The 700 mg three-times-daily arm (2,100 mg/day) was the highest dose ever formally tested in hepatitis C virus.
Primary endpoint: serum alanine aminotransferase of 45 U/L or less (considered within the normal range), or less than 65 U/L provided this was at least a 50% decline from baseline, at week 24.
Results, published in JAMA (Fried MW et al., 2012):
- Primary endpoint met by 2/52 (3.8%) placebo, 2/50 (4.0%) low-dose silymarin, and 2/52 (3.8%) high-dose silymarin — no statistically significant difference (P ≥ .99)
- HCV RNA: mean change 0.07 (placebo), -0.03 (420 mg) and 0.04 (700 mg) log10 IU/mL, no significant difference (P = .54)
- Mean serum alanine aminotransferase: mean change of -4.3 U/L (placebo), -14.4 U/L (420 mg) and -11.3 U/L (700 mg), no significant difference across the three groups (P = .75)
- Quality of life scores (Short-Form 36 and Chronic Liver Disease Questionnaire): no significant changes in any group
- Safety: the adverse event profile of silymarin was comparable with that of placebo at both doses
The conclusion: "Higher than customary doses of silymarin did not significantly reduce serum ALT levels more than placebo in participants with chronic HCV infection unsuccessfully treated with interferon-based therapy."
This was the inflection point in the milk thistle / hepatitis C virus story. SyNCH was adequately powered, properly blinded, used a high-quality standardized preparation, and tested doses up to three times the standard dose. The trial did not find an effect because there was no effect to find at any dose tested.
The published response from the integrative medicine community focused on (1) the patient selection (interferon-failed patients with advanced disease) being unfavorable for any intervention, (2) the oral bioavailability limitation of standard silymarin (the phosphatidylcholine complex was not used), and (3) the choice of alanine aminotransferase reduction as the primary endpoint when fibrosis or HCV RNA might have been more relevant. These critiques have merit, but they do not rescue the underlying claim that silymarin treats hepatitis C virus.
The Direct-Acting Antiviral (DAA) Era and the Modern Reframing
The publication of SyNCH coincided with the emergence of direct-acting antiviral (DAA) therapy for hepatitis C virus. Telaprevir and boceprevir were approved in 2011 as first-generation DAAs added to interferon-based regimens; sofosbuvir (the first nucleotide polymerase inhibitor) was approved in late 2013 as the foundation of interferon-free regimens. By 2016, multiple all-oral 8-12 week DAA combinations were curing >95% of hepatitis C virus patients across all genotypes.
This made the SyNCH negative result moot in a practical sense. Hepatitis C virus is now a curable disease for any patient with access to DAA therapy. The question of what hepatitis C virus patients could take instead of DAAs no longer needs an answer for most patients.
Milk thistle's role in hepatitis C virus has therefore been reframed in three pragmatic ways:
- Pre-DAA hepatocellular support — for patients awaiting insurance approval, or with persistently elevated alanine aminotransferase and significant symptoms while awaiting treatment, practitioners describe silymarin at standard doses as possibly giving modest symptomatic and biochemical improvement during the wait. It does not affect the virus; the DAA course is what cures the infection.
- Concurrent with DAA therapy — some patients add milk thistle during their 8-12 week DAA course as general hepatoprotection. There is no evidence this helps DAA cure rates (which are already >95%), and interference has not been reported. Drug-interaction concerns are described as minimal at standard milk thistle doses: inhibition of cytochrome P450 3A4 (CYP3A4) is seen in the laboratory, while a 14-day study in nine healthy volunteers found no significant influence on CYP3A4/5 or three other P450 enzymes (Kawaguchi-Suzuki et al., 2014).
- Post-DAA cure with residual cirrhosis — patients cured of hepatitis C virus but left with cirrhosis remain at risk for hepatocellular carcinoma and decompensation. Practitioners describe silymarin as long-term hepatoprotection in this population, though no specific trials exist; the regimen they describe is standard 420 mg/day, indefinite duration, with periodic alanine aminotransferase and Child-Pugh assessment.
For the population without access to DAAs (uninsured patients in some U.S. settings, low-income countries with limited DAA access), milk thistle is used as a symptomatic add-on; the cure itself comes from DAAs, which people reach through patient-assistance programs, generic availability, or international procurement.
See our Hepatitis C page and Hepatitis overview page for the broader hepatitis C virus clinical picture.
Intravenous Silibinin in Hepatitis C Virus Salvage Therapy
A footnote to the hepatitis C virus / silymarin story: between 2008 and the DAA breakthrough, a small body of European literature explored intravenous silibinin as salvage therapy for hepatitis C virus patients with previous interferon failure, particularly in the post-transplant setting where hepatitis C virus recurrence is universal and rapid.
Ferenci and colleagues (Vienna 2008, Gastroenterology) gave intravenous (IV) silibinin at 5, 10, 15 or 20 mg/kg/day for 14 days to people who had not responded to pegylated interferon and ribavirin, adding those two drugs from day 8. The fall in HCV RNA depended on the dose. After 7 days of silibinin alone it was 2.11 log at 15 mg/kg and 3.02 log at 20 mg/kg; after 7 further days combined with pegylated interferon and ribavirin it was 3.69 and 4.85 log. HCV RNA became undetectable in 7 patients on 15 or 20 mg/kg at week 12. This was a much larger effect than ever observed with oral silymarin.
The mechanism was first hypothesized to involve direct inhibition of hepatitis C virus RNA-dependent RNA polymerase (NS5B) at the high tissue concentrations achievable with intravenous but not oral dosing. Later laboratory work changed that picture. Wagoner and colleagues (2010) found that silymarin, but not silibinin, inhibited the genotype 2a polymerase, and that silymarin's antiviral action appears to include blocking virus entry and transmission. Esser-Nobis and colleagues (2013) studied virus from a liver transplant recipient whose infection broke through on silibinin alone: it carried mutations in a different viral protein, nonstructural protein 4B (NS4B), and a mutation in the same protein gave partial resistance in cell culture, which points to a mechanism involving NS4B. The effect also differed by virus type: in that work silibinin strongly inhibited replication of genotypes 1a and 1b but barely affected genotype 2a.
The post-transplant reports are single cases. A 2011 letter (Beinhardt et al.) described intravenous silibinin alone preventing graft infection after liver transplantation in one patient with chronic hepatitis C. A 2012 report (Aghemo et al.) described the opposite in a woman with genotype 2a: after an initial fall, her HCV RNA rose steadily and silibinin was stopped after 15 days. The effect could also be transient — in the first Ferenci study, HCV RNA fell by 1.32 log on intravenous silibinin but increased again after the infusion period despite pegylated interferon and ribavirin.
This entire intravenous-silibinin-for-HCV literature was rendered obsolete by DAAs. Sofosbuvir achieved 4+ log reductions in HCV RNA at oral doses with vastly better tolerability than intravenous silibinin infusions. Intravenous silibinin is no longer used for hepatitis C virus in current practice but remains the standard antidote for amanita poisoning. The clinical-pharmacology data, however, established that silibinin at high tissue concentrations does have direct antiviral activity — just not at concentrations achievable by oral dosing.
Hepatitis B Evidence Base
The hepatitis B literature on milk thistle is smaller than the hepatitis C virus literature and considerably more heterogeneous. Hepatitis B virus is a different therapeutic challenge from hepatitis C virus because (1) most hepatitis B virus is suppressible but not curable with current antivirals (entecavir, tenofovir), (2) the principal goals of therapy are HBV DNA suppression and prevention of disease progression rather than cure, and (3) clearance of hepatitis B surface antigen (HBsAg) is the elusive functional-cure endpoint that current therapies rarely achieve.
Representative hepatitis B virus trials:
- A reported 2011 trial — described in older accounts as 60 chronic hepatitis B virus patients randomized to silymarin or placebo for 6 months, with modest alanine aminotransferase reduction and no effect on HBV DNA or HBsAg. No record of such a hepatitis B trial could be found in Europe PMC.
- Wei et al. (2013) — meta-analysis of twelve hepatitis B virus silymarin trials from Chinese and English reports. Silymarin combined with antiviral or liver-protective drugs lowered serum transaminases and fibrosis markers more than those drugs alone, and appeared safe, but the authors called the data too limited to exclude a substantial benefit or harm or to support recommending it.
- Rambaldi Cochrane Review (2007) — the same Cochrane review covering alcoholic liver disease also covered hepatitis B virus. Eighteen trials with 1,088 patients, of low methodological quality overall. No significant effect on mortality (relative risk 0.78, 95% confidence interval 0.53-1.15), complications of liver disease or liver histology. Liver-related mortality was reduced across all trials (relative risk 0.50) but not in the high-quality trials (relative risk 0.57, 95% confidence interval 0.28-1.19). Conclusion: insufficient evidence for clinical benefit in hepatitis B virus.
- Huang et al. (2024) — a Taiwanese multi-institutional hospital-records study matched 319 people with hepatitis B cirrhosis on antivirals plus silymarin (at least 30 days) to 319 on antivirals alone. The silymarin group had lower death rates at one and two years and no significant difference in liver cancer. It was retrospective, so it cannot show cause and effect.
In summary, hepatitis B virus evidence for milk thistle is weaker than the hepatitis C virus evidence base and similarly does not support use as a primary or curative treatment. Practitioners describe adjunctive use during nucleoside analog therapy (entecavir, tenofovir); randomized evidence that it changes disease trajectory is lacking.
Silybin-Phosphatidylcholine Complex (IdB 1016) and Absorption
The persistent question raised by negative oral silymarin trials is whether higher tissue concentrations of silybin would have produced different results. Free silybin is poorly absorbed: a 2017 review calls its absorption efficiency "rather low" and cites an absolute oral bioavailability of 0.95% for pure silybin in rats, and in a 1990 study in healthy volunteers less than 3% of the dose was recovered in urine. It undergoes extensive conjugation to glucuronide and sulfate forms (which retain some but not all of the parent compound's activity). The elimination half-life is given as approximately 6 hours in the 2017 review and generally less than 4 hours in the 1990 study.
The silybin-phosphatidylcholine complex (IdB 1016) is a 1:2 molar complex. The phosphatidylcholine component is described as improving the lipid-membrane partitioning of silybin during intestinal absorption. In a 1990 study in 9 healthy volunteers, single doses equal to 360 mg of silybin gave higher plasma silybin levels at all sampling times with the complex than with silymarin; a figure of approximately 4.6-fold higher silybin plasma concentrations than equimolar standard silymarin is often quoted, though that study's abstract does not give it. The complex is also described as extending serum half-life modestly.
Pharmacokinetic figures quoted for the complex:
- 120 mg of the complex (containing approximately 80 mg silybin) produces peak silybin plasma concentrations equivalent to approximately 540 mg of standard silymarin
- The improvement is most pronounced for free (non-conjugated) silybin in serum
- Hepatic tissue concentrations follow plasma levels, providing 3-5× higher liver silybin exposure
Clinical evidence for benefit of the complex beyond standard silymarin is mixed. The 2017 Wah Kheong non-alcoholic steatohepatitis trial (described on the Liver Protection page) gave silymarin 700 mg three times daily for 48 weeks; its abstract does not describe a phosphatidylcholine complex. The primary endpoint did not differ (32.7% versus 26.0%, P = .467), but significantly more patients on silymarin had reduced fibrosis on biopsy (22.4% versus 6.0%, P = .023) and on liver stiffness measurement (24.2% versus 2.3%, P = .002); the authors wrote that silymarin may reduce liver fibrosis but that this remains to be confirmed in a larger trial. Several small open-label hepatitis C virus pilots have suggested better transaminase responses with the complex than with equivalent oral silymarin.
On cost, the complex is roughly 3-5× the price of standard silymarin. Practitioners favor it on pharmacokinetic grounds for those who can afford it, and describe standard high-quality silymarin (80%-standardized) at higher doses (e.g., 700 mg twice daily instead of 140 mg three times daily) as reaching similar tissue exposure at lower cost.
Standardized Silymarin and Quality Differences
Essentially all rigorous clinical trials have been conducted with one original European pharmaceutical-grade standardized milk thistle extract. Its standardization specifications:
- Extracted from Silybum marianum seed (achene)
- Standardized to 70-80% silymarin content, with silymarin defined chromatographically as the sum of silybin A, silybin B, isosilybin A, isosilybin B, silychristin, and silydianin
- Silybin content is the specific marker compound, with defined minimums for both silybin A and silybin B
- Manufactured to European Pharmacopoeia specifications
The clinical importance of standardization: generic supermarket milk thistle products may contain anywhere from 30% to 80% silymarin, may not specify silybin content separately, may have wide batch-to-batch variation, and frequently do not meet the European Pharmacopoeia monograph. A 175 mg "milk thistle" capsule from a generic brand may contain anywhere from 50 mg to 140 mg of actual silymarin — a nearly threefold range, with proportionally large variation in silybin content.
Where milk thistle is being used as a defined therapeutic intervention (chronic hepatitis adjunct, non-alcoholic fatty liver disease (NAFLD), post-acute liver injury recovery), the trial evidence comes from standardized 80%-silymarin preparations that meet European Pharmacopoeia specifications and other pharmaceutical-grade products. For general "liver support" without specific therapeutic claims, people also use lower-cost standardized products; unstandardized capsules carry the wide range in silymarin content described above.
Doses Used in Trials and Described by Practitioners
Trial doses on this page: 420 mg or 700 mg of silymarin three times daily for 24 weeks (SyNCH), 700 mg three times daily for 48 weeks (Wah Kheong 2017), and 240 mg of silybin as the phosphatidylcholine complex twice daily for 7 days (Buzzelli 1993). The regimens below are what practitioners describe, reported here as information.
Pre-DAA hepatocellular support (hepatitis C virus awaiting treatment):
Described regimen: standard silymarin 420 mg/day in three divided doses, or the phosphatidylcholine complex 240-360 mg/day, until DAA therapy starts. The stated goal is modest symptom and alanine aminotransferase improvement, with no expectation of viral effect.
Concurrent with DAA therapy:
Described regimen: standard silymarin 280-420 mg/day. No documented benefit on cure rates, no documented harm. Practitioners describe stopping it if unexpected liver test changes appear during the DAA course.
Post-DAA cure with residual cirrhosis or persistent alanine aminotransferase elevation:
Described regimen: standard silymarin 420 mg/day or the phosphatidylcholine complex 240-360 mg/day, indefinite duration, with periodic checks of alanine aminotransferase, aspartate aminotransferase, and synthetic function (albumin, international normalized ratio (INR), bilirubin), alongside lifestyle changes (no alcohol, non-alcoholic fatty liver disease management if metabolic syndrome is present).
Chronic hepatitis B virus (during nucleoside analog therapy):
Described regimen: standard silymarin 420 mg/day as adjunct. It does not replace entecavir or tenofovir.
Highest-dose regimens described (non-alcoholic steatohepatitis or severe chronic disease):
The phosphatidylcholine complex 240 mg three times daily (720 mg/day total), or equivalent high-dose standard silymarin 700 mg twice daily. Practitioners sometimes combine it with N-acetylcysteine (NAC) 600 mg twice daily, alpha-lipoic acid 300-600 mg/day, selenium 200 µg/day, and vitamin E 400-800 international units (IU)/day for a full integrated hepatoprotective protocol.
How it is usually described as being taken:
• With a meal containing some fat, which is said to improve absorption
• Apart from high-fiber meals
• Spaced through the day (every 6-8 hours), given the short serum half-life
• With a bedtime dose as one of the three daily doses, in some accounts
Symptom and Quality-of-Life Effects
The endpoints where milk thistle does show consistent (if modest) benefit in chronic hepatitis are not the virologic or histologic endpoints but the symptomatic ones. Chronic hepatitis C virus and hepatitis B virus patients commonly experience fatigue, right-upper-quadrant discomfort, low-grade nausea, brain fog, and depressive symptoms — collectively sometimes called "hepatitis C virus-associated extrahepatic syndrome." Several observational studies and pilot trials report improvement in these symptoms with milk thistle.
The Hepatitis Quality of Life Questionnaire (HQLQ), Chronic Liver Disease Questionnaire (CLDQ), and Short-Form 36 (SF-36) have all been used to assess this dimension. Results are mixed but tend to favor silymarin for fatigue and general well-being scores at modest magnitudes (typically 3-8 points on 0-100 scales). The 2012 SyNCH trial did not find significant quality-of-life differences, but the trial population was interferon-failed (already a population with longstanding symptomatic disease) and the 24-week duration may have been too short for subtle quality-of-life changes.
In the HALT-C data, 17% of 1,145 people with advanced hepatitis C were using silymarin at baseline. After adjusting for age, race, education, alcohol, exercise, body mass index and smoking, users still reported less fatigue, nausea, liver pain, poor appetite and muscle and joint pain, and better general health. Their alanine aminotransferase and virus levels were the same as nonusers', and the authors note that use was self-motivated and uncontrolled.
For hepatitis C virus patients who report fatigue and general hepatic discomfort, practitioners describe a 3-month course of standard silymarin 420 mg/day, continued if the person feels better and stopped if not.
Cautions and Antiviral Drug Interactions
- DAA drug interactions — the US labels describe the modern hepatitis C virus antivirals mainly by transporter. Sofosbuvir, velpatasvir and ledipasvir are substrates of the drug transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), glecaprevir and pibrentasvir are substrates of P-gp and/or BCRP, and slow breakdown of velpatasvir by CYP2B6, CYP2C8 and CYP3A4 was seen in laboratory work. Silymarin is a weak cytochrome P450 3A4 inhibitor and modest P-gp inhibitor in vitro. Clinically significant interactions at standard milk thistle doses have not been reported; high-dose phosphatidylcholine-complex products are the setting where this theoretical concern is raised most.
- What the antiviral labels warn about — the US label of sofosbuvir-velpatasvir carries a boxed warning: hepatitis B can reactivate in people with both viruses during or after hepatitis C treatment, in some cases causing liver failure and death, and the label calls for testing everyone for hepatitis B before starting. The same label says St. John's wort may significantly lower the drug levels, reducing the effect, and that using the two together is not recommended.
- Hepatitis B virus nucleoside analogs — entecavir and tenofovir are not significantly metabolized by CYP450 and do not have clinically relevant interactions with silymarin.
- Interferon (no longer commonly used) — no documented interaction with silymarin.
- Concomitant chronic medications — many hepatitis C virus patients are on stable doses of other cytochrome P450 3A4 substrates (statins, calcium channel blockers, immunosuppressants in transplant recipients). The US tacrolimus label says CYP3A inhibitors raise tacrolimus levels, with adverse reactions including changes in kidney function and QT prolongation (a heart rhythm change). In the 14-day volunteer study, milk thistle extract had no significant effect on CYP3A4/5 activity, but nine healthy volunteers are not transplant recipients; the same concern is raised for cyclosporine.
- HCC surveillance — milk thistle does not substitute for hepatocellular carcinoma (HCC) surveillance in cirrhotic patients. Six-monthly ultrasound + alpha-fetoprotein (AFP) screening remains standard regardless of supplement use.
- Asteraceae allergy — same as for any milk thistle indication.
- Not a substitute for vaccination — for hepatitis B virus-naive patients, hepatitis B virus vaccination (a two- or three-dose series of recombinant HBsAg vaccine) is the established prevention. Milk thistle has no preventive role.
- Not a replacement for DAA therapy — silymarin does not clear the virus, and deferring a DAA cure for a course of herbal therapy leaves the infection in place. The 8-12 week DAA course delivers definitive cure at low cost (generic sofosbuvir/ledipasvir is now available globally) and minimal toxicity.
Key Research Papers
- Fried MW et al. (2012). Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 308(3):274-82. — PubMed PMID: 22797645
- Seeff LB et al. (2008). Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47(2):605-12. — PubMed PMID: 18157835
- Ferenci P et al. (2008). Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135(5):1561-7. — PubMed PMID: 18771667
- Polyak SJ, Ferenci P, Pawlotsky JM (2013). Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology 57(3):1262-71. — PubMed PMID: 23213025
- Rambaldi A, Jacobs BP, Gluud C (2007). Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007(4):CD003620. — PubMed PMID: 17943794
- Buzzelli G et al. (1993). A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31(9):456-60. — PubMed PMID: 8225695
- Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P (2011). Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol 54(3):591-2. — PubMed PMID: 21106270
- Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW (2013). Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 32(5):657-69. — PubMed PMID: 23247631
- Loguercio C, Federico A, Trappoliere M, et al. (2007). The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52(9):2387-95. — PubMed PMID: 17410454
- Wagoner J et al. (2010). Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51(6):1912-21. — PubMed PMID: 20512985
- Mayer KE, Myers RP, Lee SS (2005). Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat 12(6):559-67. — PubMed PMID: 16255756
- Wah Kheong C, Nik Mustapha NR, Mahadeva S (2017). A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 15(12):1940-1949.e8. — PubMed PMID: 28419855
- Esser-Nobis K et al. (2013). Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57(3):953-63. — PubMed PMID: 23322644
- Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M (2012). Failure of intravenous silibinin monotherapy to prevent hepatitis C genotype 2a liver graft reinfection. Hepat Mon 12(6):411-4. — PubMed PMID: 22879832
- Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E (1990). Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 15(4):333-8. — PubMed PMID: 2088770
- Bijak M (2017). Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism. Molecules 22(11):1942. — PubMed PMID: 29125572
- Huang CH, Wu VC, Wang CL, Wu CL, Huang YT, Chang SH (2024). Silymarin synergizes with antiviral therapy in hepatitis B virus-related liver cirrhosis: a propensity score matching multi-institutional study. Int J Mol Sci 25(6):3088. — PubMed PMID: 38542062
- Lewis KC, Barker LK, Jiles RB, Gupta N (2023). Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017-March 2020. Clin Infect Dis 77(10):1413-1415. — PubMed PMID: 37417196
- Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS (2014). The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity. Drug Metab Dispos 42(10):1611-6. — PubMed PMID: 25028567
- US prescribing information (DailyMed): sofosbuvir and velpatasvir; ledipasvir and sofosbuvir; glecaprevir and pibrentasvir; tacrolimus.
PubMed Topic Searches
Connections
- All Herbs
- Milk Thistle Overview
- Milk Thistle Benefits Hub
- Liver Protection & Detox
- Antioxidant & Glutathione
- Skin Health
- Hepatitis (Overview)
- Hepatitis C
- Liver Disease
- Cirrhosis
- Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis
- Hepatocellular Carcinoma
- Andrographis
- Chanca Piedra: Liver Protection and Hepatitis B — hepatitis B virus-specific antiviral mechanism, niranthin vs nucleoside analogs, trial evidence on HBsAg/HBV-DNA, and adjunctive use with entecavir/tenofovir.
- Turmeric
- Dandelion
- N-Acetylcysteine
- Glutathione
- Liver Cleansing
- Detox Protocols
- Comprehensive Metabolic Panel
- Gamma-Glutamyl Transferase (Liver Enzyme)
- History